Systemic therapy for pancreatic neuroendocrine tumors

DOI Web Site 21 References
  • IKEDA Masafumi
    Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East
  • IMAOKA Hiroshi
    Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East
  • SATAKE Tomoyuki
    Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East
  • SHIBUKI Taro
    Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East
  • SASAKI Mitsuhito
    Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East
  • WATANABE Kazuo
    Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East
  • INOUE Kanae
    Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East
  • TAIRA Tomonao
    Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East
  • YAMAGUCHI Shota
    Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East
  • FUKUSHI Koh
    Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East
  • MITSUNAGA Shuichi
    Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East

Bibliographic Information

Other Title
  • 膵NENの薬物療法

Abstract

<p>Systemic therapy for pancreatic NEN differs for pancreatic neuroendocrine tumor (NET) and pancreatic neuroendocrine carcinoma (NEC). For pancreatic NETs, treatment purpose differs between hormonal symptom control or tumor growth suppression. Somatostatin analogues are mainly for hormonal symptom control. Somatostatin analogues, molecular target agents, and cytotoxic agents are for tumor growth suppression. Proper use is guided by the treatment selection MAP for pancreatic NETs. In addition, radionuclide-labeled peptide therapy is now available in Japan, and timing of introduction is also important. Platinum-based chemotherapy is standard treatment for pancreatic NEC. Various treatments are available for pancreatic NEN, so a multidisciplinary approach that makes proper use of these treatments is required.</p>

Journal

  • Suizo

    Suizo 38 (6), 390-398, 2023-12-28

    Japan Pancreas Society

References(21)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top